MORE than 100 jobs are at risk at GSK in Ulverston following a major $350m sale to a pharmaceuticals company.

It is expected GSK will supply buyer Sandoz with the antibiotic Zinnat for another four years.

At the end of this time period, GSK's proposal is to close its cephalosporin division 'in the absence of any other alternative'. Zinnat belongs to a group of medicines known as cephalosporin antibiotics.

Sandoz, which has bought GSK's cephalosporin antibiotics business, would then begin producing Zinnat within its own network.

This would see the whole of the Ulverston site close, affecting around 130 employees.